New drug IBI133 tested in 19 patients with Hard-to-Treat cancers
NCT ID NCT06170190
First seen Nov 17, 2025 · Last updated Jun 16, 2026 · Updated 24 times
Summary
This early-phase trial tested a new drug called IBI133 in 19 adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals were to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body and whether it shows any signs of shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Liverpool Hospital
Liverpool, New South Wales, 2170, Australia
Conditions
Explore the condition pages connected to this study.